Cerebrus clinches Swiss biotech deal and agrees to takeover by Vanguard
Saturday 04 December 1999
Cerebrus, part owned by biotechnology entrepreneur Chris Evans, is to license its serotonin receptor programme, which assists the treatment of obesity, to Hoffman-La Roche. The Swiss company is to fund development and commercialisation of the treatment, while Cerebrus will receive milestone payments. Hoffman-La Roche is already a world leader in obesity treatments.
Cerebrus will receive a share of royalties of any resulting product, but revenues are not anticipated until the latter half of the next decade. Vanguard Medica is buying Cerebrus for shares worth pounds 9.6m, less than half a previous offer it is thought to have made.Dr George Poste, the chairman, will leave Cerebrus.
The deal will ease the pressure on Vanguard, which suffered a setback last month when the US Food and Drug Administration demanded that it repeat early-stage trials for frovatriptan, a migraine drug.
The deal paves the way for further acquisitions of private research outfits by the quoted biotechs, which are already in the throes of consolidation. Prolifix, an Oxfordshire-based cancer research company, was tipped as a possible target yesterday; Eli Lilly, the US pharmaceuticals group, took a stake in the company in October.
- 1 Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
- 2 Disney heiress Abigail disowns her share of family profits in West Bank company
- 3 The secret report that helps Israel hide facts
- 4 'Women should not laugh in public,' says Turkey's Deputy Prime Minister in morality speech
- 5 Israel's propaganda machine is finally starting to misfire
The secret report that helps Israel hide facts
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
A day in the life of Vladimir Putin: The dictator in his labyrinth
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
Boozy, ignorant, intolerant, but very polite – Britain as others see us
- < Previous
- Next >
iJobs Money & Business
£600 - £700 per day + competitive: Orgtel: Senior Investment Accounting Change...
£450 - £650 per day + competitive: Orgtel: My client, a leading bank, is curre...
£350 - £400 per day + competitive: Orgtel: Senior Analyst, ALM Data, Halifax, ...
£500 - £600 per day: Orgtel: Java developer - Banking - London - Up to £600/d...